BriaCell Therapeutics Corp.’s (OTCQB: BCTXF) (TSX.V: BCT) Immunotherapy for Advanced Breast Cancer Patients Showing Promising Results
Confirmation of positive proof-of-concept with lead cancer drug candidate Bria-IMT as monotherapy demonstrates promising anti-tumor activity Off-the-shelf immunotherapies provide customized, cost effective treatment options Positive efficacy data with Bria-IMT was presented at a major breast cancer conference, the 2018 San Antonio Breast Cancer Symposium BriaCell Therapeutics Corp.’s poster presentation at 2018 San Antonio Breast Cancer Symposium now available for public review Global cancer immunotherapy market projected to be worth over $119 billion by 2021 Cancer patients facing limited therapeutic options are the focus for a team of scientists and clinicians at BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a clinical-stage…